Point72 Middle East FZE’s Vaxcyte PCVX Stock Holding History

Point72 Middle East FZE’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-694	Closed	-$26K	–	1946
2023 Q1	$26K	Buy	+694	New	+$29.4K	﹤0.01%	1382

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Middle East FZE's PCVX Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 694 shares — an estimated $26K sold.

Point72 Middle East FZE first reported a position in PCVX in Q1 2023 and held it in 1 quarter. The position peaked at $26K in Q1 2023. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

Point72 Middle East FZE reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
Point72 Middle East FZE sold 694 Vaxcyte shares in Q2 2023, an estimated $26K.
Point72 Middle East FZE first reported a position in Vaxcyte in Q1 2023 and held it in 1 quarter.
Point72 Middle East FZE's Vaxcyte position peaked at $26K in Q1 2023.
197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.